Skip to main content
William Kennedy, MD, Pediatrics, San Francisco, CA

WilliamKennedyMD

Pediatrics San Francisco, CA

Pediatric Infectious Disease

Senior Vice President Clinical Development

Dr. Kennedy is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Kennedy's full profile

Already have an account?

Summary

  • Pediatric Infectious Diseases - academic training and experience.

    Clinical Researcher, small and large molecule platforms and gene therapy with biologics, in pharmaceutical industry. Key contributor to development and launch of the sedative "Belsomra" or suvorexant (orexin antagonist).

    Academic biochemist and structural biologist in macromolecular crystallography and 3D NMR spectroscopy.

Education & Training

  • Yale-New Haven Medical Center
    Yale-New Haven Medical CenterFellowship, Pediatric Infectious Diseases, 1998 - 2001
  • Duke University Hospital
    Duke University HospitalInternship, Transitional Year, 1992 - 1993
  • Stanford University School of Medicine
    Stanford University School of MedicineClass of 1992

Certifications & Licensure

  • TX State Medical License
    TX State Medical License 2005 - 2024
  • CT State Medical License
    CT State Medical License 2001 - 2024

Clinical Trials

Publications & Presentations

PubMed

Authored Content

  • Assessment of the Abuse Potential of the Orexin Receptor Antagonist, Suvorexant, Compared With Zolpidem in a Randomized Crossover StudyAugust 2016

Press Mentions

  • Excision BioTherapeutics Appoints Biotechnology Industry Research & Development Veteran, William Kennedy, M.D., as Senior Vice President, Clinical Development
    Excision BioTherapeutics Appoints Biotechnology Industry Research & Development Veteran, William Kennedy, M.D., as Senior Vice President, Clinical DevelopmentApril 2nd, 2021

Grant Support

  • Phase 1 Clinical Research Program for Functional Cure of HIV with in vivo Gene TherapyCalifornia Institute of Regenerative Medicine2022–2026

Research History

  • Senior Vice President, clinical development at excision BiotherapeuticsHIV cure paradigm using CRISPRCas9 genome excision of provirus HIV1

Professional Memberships

  • International AIDS Society
    Member

Industry Relationships

  • Senior Vice President, Excision BiotherapeuticsFunctional cure of latent infectious diseases with CRISPR-SaCas9 [HIV, HBV, HSV]Disclosure: Excision Biotherapeutics- current2021 - Present